---
title: "Daiwa: Raises TIGERMED target price to HKD 45 and upgrades revenue forecast"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277711092.md"
description: "Daiwa released a research report stating that it has raised its revenue forecast for TIGERMED for 2026 to 2027 by 1% to 7%, but lowered its earnings per share forecast for the same period by 8% to 12%, due to a reduction in gross margin and an increase in sales, administrative expenses, and R&D expenses. It maintains a \"Hold\" rating, with a target price raised from HKD 38 to HKD 45. TIGERMED issued a positive profit alert, expecting a year-on-year revenue growth of 1% to 16% in 2025, reaching RMB 6.66 billion to 7.68 billion (same below), regaining growth after an 11% decline in 2024. It is expected that net profit will increase by 105% to 204% year-on-year, reaching RMB 830 million to 1.23 billion; recurring net profit is expected to decline by 43% to 61% year-on-year, reaching RMB 330 million to 490 million, mainly due to order cancellations, a decrease in order prices, and increased operating costs related to team expansion. Looking ahead to 2026, the firm estimates that the company's revenue will grow by 16% year-on-year to approximately RMB 8 billion, with net profit increasing by 14%, and net profit margin narrowing by 1 percentage point year-on-year to 15%"
datetime: "2026-03-04T02:28:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277711092.md)
  - [en](https://longbridge.com/en/news/277711092.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277711092.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/277711092.md) | [English](https://longbridge.com/en/news/277711092.md)


# Daiwa: Raises TIGERMED target price to HKD 45 and upgrades revenue forecast

According to the Zhitong Finance APP, Daiwa released a research report stating that it has raised its revenue forecast for TIGERMED (03347) for 2026 to 2027 by 1% to 7%, but lowered its earnings per share forecast for the same period by 8% to 12%, due to a reduction in gross margin and an increase in sales, administrative expenses, and R&D expenses. It maintains a "Hold" rating, with a target price raised from HKD 38 to HKD 45.

TIGERMED announced a positive earnings forecast, expecting a year-on-year revenue growth of 1% to 16% in 2025, reaching RMB 6.66 billion to 7.68 billion (the same below), regaining growth after an 11% decline in 2024. It is expected that net profit will increase by 105% to 204% year-on-year, reaching RMB 830 million to 1.23 billion; recurring net profit is expected to decline by 43% to 61% year-on-year, reaching RMB 330 million to 490 million, mainly due to order cancellations, a decrease in order prices, and increased operating costs related to team expansion. Looking ahead to 2026, the firm estimates that the company's revenue will grow by 16% year-on-year to approximately RMB 8 billion, with net profit increasing by 14%, and the net profit margin narrowing by 1 percentage point year-on-year to 15%

### 相關股票

- [TIGERMED (03347.HK)](https://longbridge.com/zh-HK/quote/03347.HK.md)

## 相關資訊與研究

- [CanSinoBIO: From Profit Turnaround to Value Realization as an Innovative Vaccine Leader](https://longbridge.com/zh-HK/news/281103901.md)
- [Accel Group Revamps Board and Committee Structure for 2026](https://longbridge.com/zh-HK/news/281408484.md)
- [Styland Subsidiary Commits US$3.4 Million to Alpha Perpetual Income Fund](https://longbridge.com/zh-HK/news/281380835.md)
- [Ganfeng Lithium Turns to 2025 Profit](https://longbridge.com/zh-HK/news/281121946.md)
- [Japan's Industrial Production Gains 0.3% on Year in February](https://longbridge.com/zh-HK/news/281095518.md)